{"page":{"totalFilteredElements":384},"studies":[{"active":true,"description":"
Register und Biomaterialdatenbank für reifzellige systemische T-Zell Lymphome (T-NHL) der German Lymphoma Alliance (GLA) und der Ostdeutschen Studiengruppe Hämatologie und Onkologie (OSHO)

DRKS00030561
","eudractNumber":null,"id":8286,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-07-14T13:56:45+02:00","shortTitle":"T-NHL Register (OSHO & GLA)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Entschlüsselung der gestörten Signalwege des Knochenmarkmikromilieus und des Zusammenspiels zwischen hämatopoetischen und stromalen Zellen bei Myelodysplastischem Syndrom (MDS) und Akuter Myeloischer Leukämie (AML)","eudractNumber":null,"id":9066,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-06-01T12:53:12+02:00","shortTitle":"TET2","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Therapie refraktärer Virusinfektionen nach allogener Stammzelltransplantation mit multispezifischen T-Zellen gegen CMV, EBV und ADV: eine Phase III, prospektive, multizentrische klinische Studie
DRKS00018985
","eudractNumber":"2018-000853-29","id":8206,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04832607","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-02-01T15:11:32+01:00","shortTitle":"TRACE","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"
A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma

","eudractNumber":"2022-502681-24-00","id":7759,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05338775","phase":{"id":"ph_6","name":"Phase IB"},"recruitmentStart":"2022-07-06T15:14:55+02:00","shortTitle":"TRIMM-3, 64407564MMY1005","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A randomized controlled study evaluationg the effectiveness of typology-Based coaching on therapy management for patients with HRpos/HER2neg early breast cancer under adjuvant treatment with Ribociclib","eudractNumber":"2024-520290-12-00","id":12014,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_17","name":"III/IV"},"recruitmentStart":null,"shortTitle":"TYPER","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"nNGM Task Force 5 Genetic Tumor Risk","eudractNumber":null,"id":8781,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-10-16T09:43:41+02:00","shortTitle":"Task Force 5 (nNGM)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"In der klinischen Studie TelePeriOP wird untersucht, ob der gezielte Einsatz von Telemedizin in Verbindung mit einem Clinical Decision Support Tool (CDS Tool) und Künstlicher Intelligenz (KI) die Qualität der präoperativen Versorgung von Patientinnen und Patienten verbessern kann. Das Hauptziel besteht darin unnötige Vor-Ort-Termine sowie Anreise- und Wartezeiten für Patientinnen und Patienten zu reduzieren.

DRKS00036500
","eudractNumber":null,"id":12239,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-04-20T13:47:49+02:00","shortTitle":"Tele-PeriOP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective, single-arm, multi-centre, blinded, observational, diagnostic accuracy study with a diagnostic medical product.
CHIRURGISCHE STUDIE
","eudractNumber":null,"id":9145,"indications":[{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04845867","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-05T12:41:27+01:00","shortTitle":"Thyroid HEmorrhage DetectOr Study (HEDOS)","therapeutical":true,"therapyLines":[]},{"active":true,"description":"A prospective, non interventional study of tivozanib monotherapy as first-line therapy for patients with advanced renal cell carcinoma and with favorable or intermediate IMDC risk","eudractNumber":null,"id":11560,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T09:28:53+02:00","shortTitle":"Tivoli","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
A Phase 3 Randomized Study Comparing JNJ-79635322 and 
an anti-BCMA AxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
","eudractNumber":"2025-522007-18","id":11964,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07258511","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-06-23T12:17:39+02:00","shortTitle":"Trilogy-4","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]}]}